Avrukibart vs tildrakizumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: IL-23 p19 · full Psoriasis pipeline

Avrukibart

Developed by Oruka Therapeutics

Phase 2 in Psoriasismonoclonal antibody
Partial signal

NCT07090330 · Phase 2 · active, not recruiting

This was a randomized, double-blind Phase 2 trial with 80 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-04-27. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Next expected readout: May 2030 · NCT07449702 (registry estimate)

Reported efficacy

Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16: Primary endpoint PASI 100 at week 16 (interim analysis): 63.5% (40/63) with ORKA-001 vs 1 of 21 with placebo (2026-04-27). (met)

Result source: NCT07090330

tildrakizumab · Ilumya

Marketed by Sun Pharmaceutical Industries and partners

Approved in Psoriasismonoclonal antibody
Reliable signal

NCT01729754 · Phase 3 · completed

This was a large, randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial (N=1,090) in moderate-to-severe plaque psoriasis. The primary efficacy endpoints, PASI-75 and PGA clear/minimal at Week 12, were both statistically significant in favor of tildrakizumab 200 mg and 100 mg compared with placebo (p<0.001). The strong design and positive primary results provide high-quality evidence of treatment benefit.

Next expected readout: September 2028 · NCT05390515 (registry estimate)

Reported efficacy

Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study) (Week 12 (or end of trial if prior to Week 12)); Percentage of Participants With a Physician's Global Assessment (PGA) Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 12 (Base Study) (Baseline and Week 12 (or end of trial if prior to Week 12)); Number of Participants Experiencing an Adverse Event Up to Week 12 (Base Study) (Up to 12 weeks); Number of Participants Discontinuing Study Drug Due to an Adverse Event Up to Week 12 (Base Study) (Up to 12 weeks); Number of Participants Discontinuing Study Drug Due to a Drug-Related Adverse Event (Base Study) (Up to 12 weeks): Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study) (Week 12 (or end of trial if prior to Week 12)): Tildrakizumab 200 mg (Part 1) 62.3% | Tildrakizumab 100 mg (Part 1) 63.8% vs Placebo (Part 1) 5.8% (met)

Result source: NCT01722331

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAvrukibarttildrakizumab
PASI 75—Not reported66.3% vs 4.4%+61.9 vs placebo100 mg · wk 16 · n 89NCT01225731
31 other results
  • 74.4% vs 4.4% 200 mg · wk 16 · n 86 · Phase 2 · primary NCT01225731
  • 64.4% vs 4.4% 25 mg · wk 16 · n 90 · Phase 2 · primary NCT01225731
  • 33.3% vs 4.4% 5 mg · wk 16 · n 42 · Phase 2 · primary NCT01225731
  • 67.0% vs 4.9% 100 mg · wk 16 · n 89 · Phase 2 · secondary NCT01225731
  • 60.7% vs 4.4% 100 mg · wk 12 · n 89 · Phase 2 · secondary NCT01225731
  • 61.4% vs 4.8% 100 mg · wk 12 · n 89 · Phase 2 · secondary NCT01225731
  • 47.1% vs 4.7% 100 mg · wk 8 · n 89 · Phase 2 · secondary NCT01225731
  • 25% vs 2.3% 100 mg · wk 6 · n 89 · Phase 2 · secondary NCT01225731
  • 11.2% vs 0% 100 mg · wk 4 · n 89 · Phase 2 · secondary NCT01225731
  • 1.1% vs 0% 100 mg · wk 2 · n 89 · Phase 2 · secondary NCT01225731
  • 76.2% vs 4.9% 200 mg · wk 16 · n 86 · Phase 2 · secondary NCT01225731
  • 72.1% vs 4.4% 200 mg · wk 12 · n 86 · Phase 2 · secondary NCT01225731
  • 73.5% vs 4.8% 200 mg · wk 12 · n 86 · Phase 2 · secondary NCT01225731
  • 61.5% vs 4.7% 200 mg · wk 8 · n 86 · Phase 2 · secondary NCT01225731
  • 30.9% vs 2.3% 200 mg · wk 6 · n 86 · Phase 2 · secondary NCT01225731
  • 3.5% vs 0% 200 mg · wk 4 · n 86 · Phase 2 · secondary NCT01225731
  • 0% vs 0% 200 mg · wk 2 · n 86 · Phase 2 · secondary NCT01225731
  • 65.5% vs 4.9% 25 mg · wk 16 · n 90 · Phase 2 · secondary NCT01225731
  • 58.9% vs 4.4% 25 mg · wk 12 · n 90 · Phase 2 · secondary NCT01225731
  • 59.8% vs 4.8% 25 mg · wk 12 · n 90 · Phase 2 · secondary NCT01225731
  • 35.2% vs 4.7% 25 mg · wk 8 · n 90 · Phase 2 · secondary NCT01225731
  • 20.9% vs 2.3% 25 mg · wk 6 · n 90 · Phase 2 · secondary NCT01225731
  • 11.2% vs 0% 25 mg · wk 4 · n 90 · Phase 2 · secondary NCT01225731
  • 1.1% vs 0% 25 mg · wk 2 · n 90 · Phase 2 · secondary NCT01225731
  • 35% vs 4.9% 5 mg · wk 16 · n 42 · Phase 2 · secondary NCT01225731
  • 23.8% vs 4.4% 5 mg · wk 12 · n 42 · Phase 2 · secondary NCT01225731
  • 25% vs 4.8% 5 mg · wk 12 · n 42 · Phase 2 · secondary NCT01225731
  • 12.5% vs 4.7% 5 mg · wk 8 · n 42 · Phase 2 · secondary NCT01225731
  • 12.5% vs 2.3% 5 mg · wk 6 · n 42 · Phase 2 · secondary NCT01225731
  • 0% vs 0% 5 mg · wk 4 · n 42 · Phase 2 · secondary NCT01225731
  • 0% vs 0% 5 mg · wk 2 · n 42 · Phase 2 · secondary NCT01225731
PASI 90—Not reported38.6% vs 2.4%+36.2 vs placebo100 mg · wk 16 · n 88NCT01225731
3 other results
  • 52.4% vs 2.4% 200 mg · wk 16 · n 84 · Phase 2 · secondary NCT01225731
  • 25.3% vs 2.4% 25 mg · wk 16 · n 87 · Phase 2 · secondary NCT01225731
  • 12.5% vs 2.4% 5 mg · wk 16 · n 40 · Phase 2 · secondary NCT01225731
PASI 100—Not reported14.8% vs 0%+14.8 vs placebo100 mg · wk 16 · n 88NCT01225731
3 other results
  • 16.7% vs 0% 200 mg · wk 16 · n 84 · Phase 2 · secondary NCT01225731
  • 9.2% vs 0% 25 mg · wk 16 · n 87 · Phase 2 · secondary NCT01225731
  • 5% vs 0% 5 mg · wk 16 · n 40 · Phase 2 · secondary NCT01225731
sPGA 0/1—Not reported61.8% vs 2.2%+59.6 vs placebo100 mg · wk 16 · n 89NCT01225731
3 other results
  • 74.4% vs 2.2% 200 mg · wk 16 · n 86 · Phase 2 · secondary NCT01225731
  • 57.8% vs 2.2% 25 mg · wk 16 · n 90 · Phase 2 · secondary NCT01225731
  • 33.3% vs 2.2% 5 mg · wk 16 · n 42 · Phase 2 · secondary NCT01225731
DLQI, change—Not reported-8.5 vs 1−9.5 vs placebo100 mg · wk 16 · n 88NCT01225731
3 other results
  • -8.8 vs 1 200 mg · wk 16 · n 83 · Phase 2 · secondary NCT01225731
  • -9.2 vs 1 25 mg · wk 16 · n 87 · Phase 2 · secondary NCT01225731
  • -4.9 vs 1 5 mg · wk 16 · n 40 · Phase 2 · secondary NCT01225731

PASI 75

Avrukibart
—Not reported
tildrakizumab
66.3% vs 4.4%+61.9 vs placebo100 mg · wk 16 · n 89NCT01225731
31 other results
  • 74.4% vs 4.4% 200 mg · wk 16 · n 86 · Phase 2 · primary NCT01225731
  • 64.4% vs 4.4% 25 mg · wk 16 · n 90 · Phase 2 · primary NCT01225731
  • 33.3% vs 4.4% 5 mg · wk 16 · n 42 · Phase 2 · primary NCT01225731
  • 67.0% vs 4.9% 100 mg · wk 16 · n 89 · Phase 2 · secondary NCT01225731
  • 60.7% vs 4.4% 100 mg · wk 12 · n 89 · Phase 2 · secondary NCT01225731
  • 61.4% vs 4.8% 100 mg · wk 12 · n 89 · Phase 2 · secondary NCT01225731
  • 47.1% vs 4.7% 100 mg · wk 8 · n 89 · Phase 2 · secondary NCT01225731
  • 25% vs 2.3% 100 mg · wk 6 · n 89 · Phase 2 · secondary NCT01225731
  • 11.2% vs 0% 100 mg · wk 4 · n 89 · Phase 2 · secondary NCT01225731
  • 1.1% vs 0% 100 mg · wk 2 · n 89 · Phase 2 · secondary NCT01225731
  • 76.2% vs 4.9% 200 mg · wk 16 · n 86 · Phase 2 · secondary NCT01225731
  • 72.1% vs 4.4% 200 mg · wk 12 · n 86 · Phase 2 · secondary NCT01225731
  • 73.5% vs 4.8% 200 mg · wk 12 · n 86 · Phase 2 · secondary NCT01225731
  • 61.5% vs 4.7% 200 mg · wk 8 · n 86 · Phase 2 · secondary NCT01225731
  • 30.9% vs 2.3% 200 mg · wk 6 · n 86 · Phase 2 · secondary NCT01225731
  • 3.5% vs 0% 200 mg · wk 4 · n 86 · Phase 2 · secondary NCT01225731
  • 0% vs 0% 200 mg · wk 2 · n 86 · Phase 2 · secondary NCT01225731
  • 65.5% vs 4.9% 25 mg · wk 16 · n 90 · Phase 2 · secondary NCT01225731
  • 58.9% vs 4.4% 25 mg · wk 12 · n 90 · Phase 2 · secondary NCT01225731
  • 59.8% vs 4.8% 25 mg · wk 12 · n 90 · Phase 2 · secondary NCT01225731
  • 35.2% vs 4.7% 25 mg · wk 8 · n 90 · Phase 2 · secondary NCT01225731
  • 20.9% vs 2.3% 25 mg · wk 6 · n 90 · Phase 2 · secondary NCT01225731
  • 11.2% vs 0% 25 mg · wk 4 · n 90 · Phase 2 · secondary NCT01225731
  • 1.1% vs 0% 25 mg · wk 2 · n 90 · Phase 2 · secondary NCT01225731
  • 35% vs 4.9% 5 mg · wk 16 · n 42 · Phase 2 · secondary NCT01225731
  • 23.8% vs 4.4% 5 mg · wk 12 · n 42 · Phase 2 · secondary NCT01225731
  • 25% vs 4.8% 5 mg · wk 12 · n 42 · Phase 2 · secondary NCT01225731
  • 12.5% vs 4.7% 5 mg · wk 8 · n 42 · Phase 2 · secondary NCT01225731
  • 12.5% vs 2.3% 5 mg · wk 6 · n 42 · Phase 2 · secondary NCT01225731
  • 0% vs 0% 5 mg · wk 4 · n 42 · Phase 2 · secondary NCT01225731
  • 0% vs 0% 5 mg · wk 2 · n 42 · Phase 2 · secondary NCT01225731

PASI 90

Avrukibart
—Not reported
tildrakizumab
38.6% vs 2.4%+36.2 vs placebo100 mg · wk 16 · n 88NCT01225731
3 other results
  • 52.4% vs 2.4% 200 mg · wk 16 · n 84 · Phase 2 · secondary NCT01225731
  • 25.3% vs 2.4% 25 mg · wk 16 · n 87 · Phase 2 · secondary NCT01225731
  • 12.5% vs 2.4% 5 mg · wk 16 · n 40 · Phase 2 · secondary NCT01225731

PASI 100

Avrukibart
—Not reported
tildrakizumab
14.8% vs 0%+14.8 vs placebo100 mg · wk 16 · n 88NCT01225731
3 other results
  • 16.7% vs 0% 200 mg · wk 16 · n 84 · Phase 2 · secondary NCT01225731
  • 9.2% vs 0% 25 mg · wk 16 · n 87 · Phase 2 · secondary NCT01225731
  • 5% vs 0% 5 mg · wk 16 · n 40 · Phase 2 · secondary NCT01225731

sPGA 0/1

Avrukibart
—Not reported
tildrakizumab
61.8% vs 2.2%+59.6 vs placebo100 mg · wk 16 · n 89NCT01225731
3 other results
  • 74.4% vs 2.2% 200 mg · wk 16 · n 86 · Phase 2 · secondary NCT01225731
  • 57.8% vs 2.2% 25 mg · wk 16 · n 90 · Phase 2 · secondary NCT01225731
  • 33.3% vs 2.2% 5 mg · wk 16 · n 42 · Phase 2 · secondary NCT01225731

DLQI, change

Avrukibart
—Not reported
tildrakizumab
-8.5 vs 1−9.5 vs placebo100 mg · wk 16 · n 88NCT01225731
3 other results
  • -8.8 vs 1 200 mg · wk 16 · n 83 · Phase 2 · secondary NCT01225731
  • -9.2 vs 1 25 mg · wk 16 · n 87 · Phase 2 · secondary NCT01225731
  • -4.9 vs 1 5 mg · wk 16 · n 40 · Phase 2 · secondary NCT01225731
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Avrukibart
Primary endpoint PASI 100 at week 16 (interim analysis): 63.5% (40/63) with ORKA-001 vs 1 of 21 with placebo (2026-04-27). NCT07090330 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Avrukibart: 0 of 4 rows · tildrakizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metrictildrakizumab
Dropout rate
—100 mga
NCT01729754 · Phase 3 · monotherapy
show 24 more results
—200 mg
NCT01729754 · Phase 3 · monotherapy
—100 mg
NCT01722331 · Phase 3 · monotherapy
—100 mg
NCT01722331 · Phase 3 · monotherapy
—100 mg
NCT01722331 · Phase 3 · monotherapy
—200 mg
NCT01722331 · Phase 3 · monotherapy
—200 mg
NCT01722331 · Phase 3 · monotherapy
—200 mg
NCT01722331 · Phase 3 · monotherapy
15.7%100 mg
NCT03897075 · Phase 3
—100 mg
NCT03897075 · Phase 3
16.7%
NCT04271540 · Phase 4 · registry result, not featured evidence
0%
NCT04541329 · Phase 4 · registry result, not featured evidence
18.2%100 mg
NCT03718299 · Phase 4 · registry result, not featured evidence
1.1%100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
2.3%200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
5.4%25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
4.8%5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—100 mga
NCT01729754 · Phase 3 · monotherapy
show 24 more results
—200 mg
NCT01729754 · Phase 3 · monotherapy
—100 mg
NCT01722331 · Phase 3 · monotherapy
—100 mg
NCT01722331 · Phase 3 · monotherapy
—100 mg
NCT01722331 · Phase 3 · monotherapy
—200 mg
NCT01722331 · Phase 3 · monotherapy
—200 mg
NCT01722331 · Phase 3 · monotherapy
—200 mg
NCT01722331 · Phase 3 · monotherapy
—100 mg
NCT03897075 · Phase 3
—100 mg
NCT03897075 · Phase 3
—
NCT04271540 · Phase 4 · registry result, not featured evidence
—
NCT04541329 · Phase 4 · registry result, not featured evidence
1.8%100 mg
NCT03718299 · Phase 4 · registry result, not featured evidence
1.1%100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
1.2%200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
2.2%25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
2.4%5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
Serious AEs
6.2%100 mga
NCT01729754 · Phase 3 · monotherapy
show 24 more results
4.9%200 mg
NCT01729754 · Phase 3 · monotherapy
1.6%100 mg
NCT01722331 · Phase 3 · monotherapy
1.9%100 mg
NCT01722331 · Phase 3 · monotherapy
4.4%100 mg
NCT01722331 · Phase 3 · monotherapy
2.6%200 mg
NCT01722331 · Phase 3 · monotherapy
2.2%200 mg
NCT01722331 · Phase 3 · monotherapy
5.8%200 mg
NCT01722331 · Phase 3 · monotherapy
—100 mg
NCT03897075 · Phase 3
5.9%100 mg
NCT03897075 · Phase 3
0%
NCT04271540 · Phase 4 · registry result, not featured evidence
0%
NCT04541329 · Phase 4 · registry result, not featured evidence
7.3%100 mg
NCT03718299 · Phase 4 · registry result, not featured evidence
1.1%100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
3.9%100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
1.5%100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
2.3%200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
3.8%200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
2.7%200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
1.1%25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
5.3%25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
1.1%25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
100 mga
nasopharyngitis 23% (placebo 7.7%)
headache 6% (placebo 3.8%)
arthralgia 5.3% (placebo 1.9%)
NCT01729754 · Phase 3 · monotherapy
show 22 more results
200 mg
nasopharyngitis 22.6% (placebo 7.7%)
headache 5.7% (placebo 3.8%)
upper respiratory tract infection 5.1% (placebo 0.6%)
NCT01729754 · Phase 3 · monotherapy
100 mg
nasopharyngitis 7.8% (placebo 5.2%)
upper respiratory tract infection 3.2% (placebo 5.8%)
psoriasis 0.6% (placebo 5.2%)
NCT01722331 · Phase 3 · monotherapy
100 mg
nasopharyngitis 6.4% (placebo 5.2%)
upper respiratory tract infection 4.3% (placebo 5.8%)
psoriasis 0.5% (placebo 5.2%)
NCT01722331 · Phase 3 · monotherapy
100 mg
nasopharyngitis 15.2% (placebo 5.2%)
upper respiratory tract infection 8.2% (placebo 5.8%)
psoriasis 2.8% (placebo 5.2%)
NCT01722331 · Phase 3 · monotherapy
200 mg
nasopharyngitis 6.5% (placebo 5.2%)
upper respiratory tract infection 4.9% (placebo 5.8%)
psoriasis 0% (placebo 5.2%)
NCT01722331 · Phase 3 · monotherapy
200 mg
upper respiratory tract infection 5.4% (placebo 5.8%)
nasopharyngitis 4.6% (placebo 5.2%)
psoriasis 0.8% (placebo 5.2%)
NCT01722331 · Phase 3 · monotherapy
200 mg
nasopharyngitis 12.2% (placebo 5.2%)
upper respiratory tract infection 10.3% (placebo 5.8%)
psoriasis 2.5% (placebo 5.2%)
NCT01722331 · Phase 3 · monotherapy
100 mg
covid-19 11.8% (placebo 10.4%)
skin and subcutaneous tissue disorders 9.8% (placebo 4.2%)
upper respiratory tract infection 9.8% (placebo 8.3%)
NCT03897075 · Phase 3
covid infection 9.7%
NCT04271540 · Phase 4 · registry result, not featured evidence
100 mg
psoriasis 12.7%
hypertension 9.1%
dermatitis 5.5%
NCT03718299 · Phase 4 · registry result, not featured evidence
100 mg
nasopharyngitis 14.6% (placebo 20%)
diarrhoea 6.7% (placebo 6.7%)
headache 6.7% (placebo 8.9%)
NCT01225731 · Phase 2 · registry result, not featured evidence
100 mg
nasopharyngitis 22.2% (placebo 20%)
headache 8.5% (placebo 8.9%)
back pain 5.2% (placebo 0%)
NCT01225731 · Phase 2 · registry result, not featured evidence
100 mg
nasopharyngitis 8.8% (placebo 20%)
back pain 3.6% (placebo 0%)
headache 3.6% (placebo 8.9%)
NCT01225731 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 12.8% (placebo 20%)
headache 8.1% (placebo 8.9%)
pruritus 4.7% (placebo 8.9%)
NCT01225731 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 16.5% (placebo 20%)
gastroenteritis 6.3% (placebo 2.2%)
upper respiratory tract infection 5.1% (placebo 0%)
NCT01225731 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 6.7% (placebo 20%)
upper respiratory tract infection 4% (placebo 0%)
bronchiitis 2.7% (placebo 4.4%)
NCT01225731 · Phase 2 · registry result, not featured evidence
25 mg
nasopharyngitis 13.2% (placebo 20%)
diarrhoea 5.5% (placebo 6.7%)
headache 5.5% (placebo 8.9%)
NCT01225731 · Phase 2 · registry result, not featured evidence
25 mg
nasopharyngitis 25.5% (placebo 20%)
gastroenteritis 5.3% (placebo 2.2%)
back pain 4.3% (placebo 0%)
NCT01225731 · Phase 2 · registry result, not featured evidence
25 mg
nasopharyngitis 6.9% (placebo 20%)
back pain 3.4% (placebo 0%)
bronchiitis 2.3% (placebo 4.4%)
NCT01225731 · Phase 2 · registry result, not featured evidence
5 mg
nasopharyngitis 16.7% (placebo 20%)
bronchiitis 7.1% (placebo 4.4%)
cough 7.1% (placebo 4.4%)
NCT01225731 · Phase 2 · registry result, not featured evidence
5 mg
nasopharyngitis 23.1% (placebo 20%)
acute tonsilitis 7.7% (placebo 0%)
blood pressure systolic increased 7.7% (placebo 0%)
NCT01225731 · Phase 2 · registry result, not featured evidence
5 mg
abdominal pain upper 8.3% (placebo 0%)
back pain 8.3% (placebo 0%)
dyspnoea 8.3% (placebo 0%)
NCT01225731 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

tildrakizumab

PASI 75 61.2% (n=307) vs 5.8% (n=156) placebo @ 12wk100 mg
responder rate · % of participants
Extension (open-label)
NCT01729754 · Phase 3 · monotherapy
show 5 more results
73.5% (n=294) vs 53.6% (n=289) Etanercept @ 28wk100 mg
NCT01729754 · Phase 3 · monotherapy
63.8% (n=309) vs 5.8% (n=154) placebo @ 12wk100 mg
NCT01722331 · Phase 3 · monotherapy
65.6% (n=314) vs 5.8% (n=156) placebo @ 12wk200 mg
NCT01729754 · Phase 3 · monotherapy
72.6% (n=299) vs 53.6% (n=289) Etanercept @ 28wk200 mg
NCT01729754 · Phase 3 · monotherapy
62.3% (n=308) vs 5.8% (n=154) placebo @ 12wk200 mg
NCT01722331 · Phase 3 · monotherapy
sPGA 0/1 54.7% (n=307) vs 4.5% (n=156) placebo @ 12wk100 mg
responder rate · % of participants
Extension (open-label)
NCT01729754 · Phase 3 · monotherapy
show 5 more results
64.6% (n=294) vs 45.3% (n=289) Etanercept @ 28wk100 mg
NCT01729754 · Phase 3 · monotherapy
57.9% (n=309) vs 7.1% (n=154) placebo @ 12wk100 mg
NCT01722331 · Phase 3 · monotherapy
59.2% (n=314) vs 4.5% (n=156) placebo @ 12wk200 mg
NCT01729754 · Phase 3 · monotherapy
69.2% (n=299) vs 45.3% (n=289) Etanercept @ 28wk200 mg
NCT01729754 · Phase 3 · monotherapy
59.1% (n=308) vs 7.1% (n=154) placebo @ 12wk200 mg
NCT01722331 · Phase 3 · monotherapy
PASI 75 97.6% (n=212) @ 40wk100 mg
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT01729754 · Phase 3 · monotherapy
show 11 more results
66.7% (n=21) @ 40wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
61.9% (n=21) @ 40wk100 mg
NCT01729754 · Phase 3 · monotherapy
93.6% (n=204) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
78.9% (n=19) @ 52wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
68.4% (n=19) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
96.3% (n=107) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
92.6% (n=108) @ 40wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
63.3% (n=60) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
97.1% (n=105) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
94.2% (n=104) @ 52wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
66.7% (n=60) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
sPGA 0/1 84.9% (n=212) @ 40wk100 mg
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT01729754 · Phase 3 · monotherapy
show 11 more results
38.1% (n=21) @ 40wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
57.1% (n=21) @ 40wk100 mg
NCT01729754 · Phase 3 · monotherapy
79.4% (n=204) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
42.1% (n=19) @ 52wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
57.9% (n=19) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
83.2% (n=107) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
79.2% (n=106) @ 40wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
57.6% (n=59) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
84.8% (n=105) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
77.7% (n=103) @ 52wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
50.8% (n=59) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
PASI 90 38.8% (n=307) vs 1.3% (n=156) placebo @ 12wk100 mg
responder rate · % of participants
Extension (open-label)
NCT01729754 · Phase 3 · monotherapy
show 5 more results
55.5% (n=290) vs 30.7% (n=277) Etanercept @ 28wk100 mg
NCT01729754 · Phase 3 · monotherapy
34.6% (n=309) vs 2.6% (n=154) placebo @ 12wk100 mg
NCT01722331 · Phase 3 · monotherapy
36.6% (n=314) vs 1.3% (n=156) placebo @ 12wk200 mg
NCT01729754 · Phase 3 · monotherapy
57.7% (n=293) vs 30.7% (n=277) Etanercept @ 28wk200 mg
NCT01729754 · Phase 3 · monotherapy
35.4% (n=308) vs 2.6% (n=154) placebo @ 12wk200 mg
NCT01722331 · Phase 3 · monotherapy
PASI 90 78.8% (n=212) @ 40wk100 mg
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT01729754 · Phase 3 · monotherapy
show 11 more results
23.8% (n=21) @ 40wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
42.9% (n=21) @ 40wk100 mg
NCT01729754 · Phase 3 · monotherapy
78.4% (n=204) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
26.3% (n=19) @ 52wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
42.1% (n=19) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
76.6% (n=107) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
73.1% (n=108) @ 40wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
28.3% (n=60) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
81.9% (n=105) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
68.3% (n=104) @ 52wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
31.7% (n=60) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
PASI 100 12.4% (n=307) vs 0% (n=156) placebo @ 12wk100 mg
responder rate · % of participants
Extension (open-label)
NCT01729754 · Phase 3 · monotherapy
show 5 more results
22.8% (n=290) vs 11.2% (n=277) Etanercept @ 28wk100 mg
NCT01729754 · Phase 3 · monotherapy
13.9% (n=309) vs 1.3% (n=154) placebo @ 12wk100 mg
NCT01722331 · Phase 3 · monotherapy
11.8% (n=314) vs 0% (n=156) placebo @ 12wk200 mg
NCT01729754 · Phase 3 · monotherapy
27% (n=293) vs 11.2% (n=277) Etanercept @ 28wk200 mg
NCT01729754 · Phase 3 · monotherapy
14% (n=308) vs 1.3% (n=154) placebo @ 12wk200 mg
NCT01722331 · Phase 3 · monotherapy
PASI 100 33.5% (n=212) @ 40wk100 mg
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT01729754 · Phase 3 · monotherapy
show 11 more results
0% (n=21) @ 40wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
14.3% (n=21) @ 40wk100 mg
NCT01729754 · Phase 3 · monotherapy
35.3% (n=204) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
5.3% (n=19) @ 52wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
31.6% (n=19) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
39.3% (n=107) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
38.9% (n=108) @ 40wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
11.7% (n=60) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
46.7% (n=105) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
37.5% (n=104) @ 52wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
10% (n=60) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
DLQI -10.2 vs -2 placebo score @ 12wk100 mg
absolute change · score
Extension (open-label)
NCT01729754 · Phase 3 · monotherapy
show 5 more results
-11.2 vs -9.5 Etanercept score @ 28wk100 mg
NCT01729754 · Phase 3 · monotherapy
-9.8 vs -2.3 placebo score @ 12wk100 mg
NCT01722331 · Phase 3 · monotherapy
-10.3 vs -2 placebo score @ 12wk200 mg
NCT01729754 · Phase 3 · monotherapy
-11.7 vs -9.5 Etanercept score @ 28wk200 mg
NCT01729754 · Phase 3 · monotherapy
-10 vs -2.3 placebo score @ 12wk200 mg
NCT01722331 · Phase 3 · monotherapy
DLQI -13.2 score @ 40wk100 mg
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT01729754 · Phase 3 · monotherapy
show 11 more results
-9 score @ 40wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
-9.8 score @ 40wk100 mg
NCT01729754 · Phase 3 · monotherapy
-13.1 score @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
-9.4 score @ 52wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
-9.3 score @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
-11.6 score @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
-12 score @ 40wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
-9.7 score @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
-11.3 score @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
-11.5 score @ 52wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
-9.2 score @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
DLQI 0/1 40.2% (n=296) vs 8% (n=150) placebo @ 12wk100 mg
responder rate · % of participants
Extension (open-label)
NCT01729754 · Phase 3 · monotherapy
show 5 more results
54.1% (n=290) vs 39.4% (n=282) Etanercept @ 28wk100 mg
NCT01729754 · Phase 3 · monotherapy
41.5% (n=304) vs 5.3% (n=150) placebo @ 12wk100 mg
NCT01722331 · Phase 3 · monotherapy
47.4% (n=306) vs 8% (n=150) placebo @ 12wk200 mg
NCT01729754 · Phase 3 · monotherapy
65% (n=297) vs 39.4% (n=282) Etanercept @ 28wk200 mg
NCT01729754 · Phase 3 · monotherapy
44.2% (n=299) vs 5.3% (n=150) placebo @ 12wk200 mg
NCT01722331 · Phase 3 · monotherapy
DLQI 0/1 71.2% (n=212) @ 40wk100 mg
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT01729754 · Phase 3 · monotherapy
show 11 more results
9.5% (n=21) @ 40wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
19% (n=21) @ 40wk100 mg
NCT01729754 · Phase 3 · monotherapy
68.8% (n=205) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
10.5% (n=19) @ 52wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
42.1% (n=19) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
72.2% (n=108) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
68.5% (n=108) @ 40wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
41.7% (n=60) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
72.4% (n=105) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
71.4% (n=105) @ 52wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
40% (n=60) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy

+ 33 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Avrukibart's landscape · tildrakizumab's landscape